The Summary of Product Characteristics (SPC) for ELREXFIO, 40 mg/mL solution for injection is available here.
ELREXFIO (elranatanab) is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
*Contact Medical Information. 09h - 18h Monday to Friday.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
www.pfizersafetyreporting.com
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at
[email protected].
You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr